SINPAIN at ESB 2025

On 7-11 September 2025, SINPAIN participated in the 34th Annual Conference of the European Society for Biomaterials (ESB), in Turin, Italy.

This year’s ESB topic “Biomaterials on the horizon” opened the floor for an exciting exchange among participants in the areas of clinical translation, regenerative medicine, in vitro models, drug delivery, antibacterial treatments as well as biomaterials-assisted gene and cell therapy and investigations at the (bio)molecular and cell scale. Cross-cutting topics included the use of artificial intelligence in biomaterial research, ethics and the 3Rs principle.

As part of Session Roma13 on “ESB-EORS clinical bridge: Unmet clinical needs and new biomaterials solutions in the treatment of osteoarthritis” Daniela Vasconcelos from SINPAIN partner i3S contributed with a presentation on “Gene Silencing in Primary Human Macrophages via siRNA-Lipid Nanoparticles: A Novel therapeutic Strategy for Knee Osteoarthritis”. In this contribution, she showed the latest in vitro efficacy results of SINPAIN therapy for osteoarthritis. Her findings showed a strong downregulation of IL1B, a key driver of OA, in LPS-primed primary human macrophages. This highlights the potential of SINPAIN’s strategy as a precise anti-inflammatory therapy for knee OA and underscores its translational promise.

Meriem Lamghari from i3S and Damien Dupin from SINPAIN coordinator CIDETEC also joined the conference to network with sister projects such as FORCE REPAIR.